Polatuzumab vedotin binds CD79b on B cells, is internalized, and releases MMAE, which binds the Vinca site on beta-tubulin to disrupt microtubules, causing G2/M arrest and apoptosis. Tubulin expression itself does not determine targeting; CD79b does.